RUTHFULLY YOURS

https://www.americanthinker.com/blog/2020/01/in_san_francisco_smell_of_poop_overpowered_by_stench_of_leftist_corruption.html

One-party blue city San Francisco has a corruption problem.

Turns out the sewage on the streets isn’t the only thing filthy about San Francisco. Its man in charge of that clean-up, Mohammed Nuru, was busted with a septic tank full of corruption charges.

According to the San Francisco Examiner:

In the biggest public corruption scandal to shake City Hall since 2015, [San Francisco Public Works Director Mohammed] Nuru and local entrepreneur Nick Bovis of famed Union Square sports bar Lefty O’Doul’s have each been charged with one count of wire fraud.

Nuru, 57, and Bovis, 56, allegedly attempted to bribe an airport commissioner to help win a bid for a restaurant lease at San Francisco International Airport in exchange for an envelope full of cash and an apparent vacation.

The alleged kickback scheme was just one of five that federal authorities described in a complaint released Tuesday after surveilling Nuru and Bovis with FBI wiretaps and undercover operators since at least 2018.

The allegations against Nuru also involve sharing a $2,070 bottle of wine with a billionaire developer in China and having city contractors work on his vacation home near the Mendocino National Forest.

The detailed descriptions of the string of corruption crimes Nuru was involved in must have made him a lawman’s dream, given the large number of violations they were able to demonstrate, a veritable sewage pit of systemic corruption. 

https://townhall.com/tipsheet/bethbaumann/2020/01/29/patrick-philbin-nails-schiff-on-whistleblower-contact-and-for-hiding-evidence-n2560358

Deputy White House Counsel Patrick Philbin shredded House Intelligence Committee Chairman and lead Impeachment Manager Adam Schiff (D-CA) for his contact with the Ukranian whistleblower, which led to the impeachment inquiry, and eventually the current trial. As it currently sits, we are still in the dark about what role Schiff and his staff played in the whistleblower’s inquiry. 

Sen. Mike Lee (R-UT) presented the question on behalf of Sens. Ted Cruz (R-TX) and Josh Hawley (R-MO).

“Is it true that Shawn Misco and Abigail Grace and the alleged whistleblower were employed by or detailed by the National Security Council in the same time period of January 20, 2017 and the present? Do you have reason to believe they knew each other and have any reason to believe that alleged whistleblower and Misco did everything they could to ‘take out the president’?

“Mr. Chief Justice, Senators, the only knowledge that we have of this comes from public reports. I gather that there is a news report in some publication that suggests a name for the whistleblower and suggests where he worked and that he worked at that time while detail of the NSC staff for Vice President Biden and others who worked there,” Philbin explained. “We have no knowledge of that other than what is in the public reports, and I don’t want to get into speculating about that.”

https://issuesinsights.com/2020/01/30/feeling-the-pain-of-high-drug-prices-we-prescribe-market-forces/

Trump administration officials keep searching for solutions to rising prescription drug prices, which are increasing faster than inflation. “Drug makers and companies are not living up to their commitments on pricing. Not being fair to the consumer, or to our Country!” President Donald Trump tweeted last year.  

However, it’s hard to know what “fair” prices are. After all, pharmaceutical research and development is expensive and high risk. Bringing a drug to market may take 10 or more years and costs, on average, more than $2.5 billion. Most of the administration’s suggested remedies have been threats of the imposition of various types of price controls. (Predictably, those proposed by the Democrat presidential hopefuls have been much more draconian.)

A conservative, reform-minded administration should know better than to go down the path of innovation-stifling, heavy-handed government intervention. Responsible regulatory reform is a better way to foster pharmaceutical innovation, drive prices down, and help patients.  

We suggest two ways to do that. 

The first would be to correct a glitch in patent laws. Patents are granted to inventors by the U.S. Patent and Trademark Office if their product or process is judged to be useful, novel and non-obvious. The driver of pharmaceutical R&D investment is the promise that after a drug receives Food and Drug Administration approval, a manufacturer will be able to market it exclusively, without generic competition, for a period of time at the price it chooses. After the patent expires, the introduction of generic versions of the drug reduces drug prices dramatically.